RUNX1 knockdown sensitized cells to inhibition by the FAK inhibitors VS-4718 and defactinib (Fig. 8E–F), suggesting that these inhibitors may be efficacious in AML cases with loss-of-function RUNX1 and possibly TP53 mutations. Here, PTK2 is linked to acute myeloid leukemia.